Gynecologic Cancers
Meeting the Toxicity Challenge Posed by Antibody–Drug Conjugates
Antibody–drug conjugates have yielded improved survival rates in patients with gynecologic malignancies, but pharmacists must help patients cope with associated toxicities.
JULY 4, 2025
Rates of Cervical Precancers Have Fallen Drastically During Vaccine Age
During 2008-2022, cervical precancer incidence decreased by 79% and higher grade precancer incidence dropped by 80% among screened women between 20 and 24 years of age, probably due to HPV vaccination.
JUNE 2, 2025
FDA Grants Accelerated Approval to Avmapki Fakzynja Co-pack for Some Ovarian Cancers
The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem) for adult patients with KRAS-mutated, recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
MAY 8, 2025
Schistosomiasis Alters Genes Related to Cervical Cancer
Schistosoma haematobium infection can trigger cancer-related gene activity in the cervical lining, with changes becoming even more pronounced after treatment.
MAY 2, 2025
Overall Survival Benefit Supports New Standard in High-Risk, Locally Advanced Cervical Cancer
In patients with high risk, locally advanced cervical cancer, previously reported data demonstrated an advantage for the immune checkpoint inhibitor pembrolizumab (Keytruda, Merck) over concurrent chemoradiotherapy (CCRT) alone for progression-free survival (PFS), but mature data now show the efficacy advantage extends to overall survival (OS).
OCTOBER 10, 2024
FDA Expands Endometrial Cancer Indication for Jemperli With Chemotherapy
The FDA has approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent endometrial cancer.
AUGUST 1, 2024
FDA Approves Keytruda With Chemo for Primary Advanced or Recurrent Endometrial Carcinoma
The FDA has approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma.
JUNE 18, 2024
FDA Approves Imfinzi With Chemo for dMMR Primary Advanced or Recurrent Endometrial Cancer
The FDA has approved durvalumab (Imfinzi, AstraZeneca UK Limited) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair–deficient (dMMR).
JUNE 17, 2024
FDA Fully Approves Tivdak for Recurrent or Metastatic Cervical Cancer
The FDA has granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen [now part of Pfizer]) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for this indication.
MAY 1, 2024
Elahere Fully Approved for Certain Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The FDA approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRalpha-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
MARCH 25, 2024
Keytruda With Chemoradiotherapy Approved for FIGO 2014 Stage III-IVA Cervical Cancer
The FDA approved pembrolizumab (Keytruda, Merck) with chemoradiotherapy (CRT) for patients with FIGO 2014 stage III to IVA cervical cancer.
JANUARY 17, 2024
In Recurrent/Metastatic Cervical Cancer, Tisotumab Vedotin Improves Survival
In patients with recurrent or metastatic cervical cancer, treatment with the antibody–drug conjugate tisotumab vedotin-tftv (Tivdak, Seagen/Genmab) reduced the risk for death by 30% compared with investigator’s choice chemotherapy, according to results of the phase 3 innovaTV 301 trial.
NOVEMBER 6, 2023
